Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

MOTS-c versus Humanin

MOTS-c vs Humanin — Two Mitochondrial-Derived Peptides Compared

MOTS-c and humanin are peptides encoded in mitochondrial DNA. Compared: what each does in cells and rodents, what has been studied in people, and one cancer-related safety signal.

Save
FeatureMOTS-cHumanin
Length16 amino acids (PMID 25738459)24 amino acids (PMID 15153530). Six related small humanin-like peptides are encoded in the same region (PMID 27070352)
Where it is encodedWithin the mitochondrial 12S rRNA region (PMID 25738459)Within the mitochondrial 16S rRNA region (PMID 27070352)
First reported2015, Lee and colleagues (PMID 25738459)2001, Hashimoto and colleagues, in a screen for factors that protect neurons from Alzheimer's disease-related toxicity (PMID 11371646)
Reported mechanismIn cells and mice, inhibition of the folate cycle and of purine synthesis, leading to AMPK activation (PMID 25738459)In cell studies, binds formyl peptide receptor-like 1 and 2 (PMID 15153530; PMID 15465011) and a CNTFR/WSX-1/gp130 receptor complex (PMID 19386761)
What the studies focus onInsulin sensitivity and metabolic homeostasis, mainly in skeletal muscle, in mice (PMID 25738459)Cell survival under toxic stimuli, in cells and animals (PMID 30582721). A humanin analogue also improved insulin sensitivity in rodents (PMID 19623253)
Level in the body with agePlasma level reported to fall with age (PMID 36761202)Circulating level fell with age in humans and mice (PMID 19623253)
ExerciseRaised in muscle and plasma after acute high-intensity exercise in humans; effects of training are conflicting (PMID 34520826)Same review: raised after acute high-intensity exercise; effects of training are conflicting (PMID 34520826)
Given to people in a published studyNone found (PubMed, 6 November 2026)None found (PubMed, 6 November 2026)
Cancer-related findingNone reported in the papers citedAccelerated tumour growth and lung metastases in a mouse model of triple-negative breast cancer (PMID 32444831)

Both are mitochondrial-derived peptides, but not interchangeable

MOTS-c and humanin are both short peptides encoded within mitochondrial DNA rather than the nuclear genome. MOTS-c was reported in 2015 as a 16-amino-acid peptide from the mitochondrial 12S rRNA region (PMID 25738459). Humanin, reported in 2001, has 24 amino acids (PMID 11371646; PMID 15153530) and comes from the 16S rRNA region, where six further small humanin-like peptides have been described (PMID 27070352). A 2022 review counts eight published mitochondrial-derived peptides: humanin, MOTS-c and the six small humanin-like peptides (PMID 35499074).

The two have been studied for different questions. MOTS-c work centres on insulin sensitivity and metabolism in mice. Humanin work centres on cell survival under toxic stress, although a humanin analogue also improved insulin sensitivity in rodents (PMID 19623253). The comparison table sets out what each peptide's own literature reports; it is not a comparison of results from the same experiment.

Mechanism side by side

In the 2015 paper, MOTS-c's cellular actions inhibited the folate cycle and the linked synthesis of purines (building blocks of DNA and RNA), leading to activation of AMPK, an enzyme that responds to the cell's energy status. The authors report skeletal muscle as its primary target organ, and MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity (PMID 25738459). That abstract describes no cell-surface receptor for MOTS-c.

For humanin, cell studies describe two receptor routes. Humanin acted through formyl peptide receptor-like 1 (a cell-surface receptor involved in immune signalling) in immune cells and neuroblast cells (PMID 15153530), and as a ligand for both receptor-like 1 and 2 in transfected cells (PMID 15465011). A separate study found that gp130, a signalling subunit shared by several cytokine receptors, was essential for humanin's protection of neurons in culture, with CNTFR and WSX-1 involved in binding (PMID 19386761). A 2019 review describes humanin as protecting many cell types from toxic stimuli and as evaluated for neurodegenerative and cardiovascular disease, diabetes, male infertility and cancer (PMID 30582721).

What has been studied in people

No published study giving either peptide to people was found. PubMed searches on 6 November 2026 for ("MOTS-c"[tiab] OR "MOTSc"[tiab]) AND clinical trial[pt] (5 records) and humanin[tiab] AND clinical trial[pt] (8 records, one shared) returned 12 different papers. Each measures the body's own peptide, in settings such as exercise, metformin treatment, heat exposure or hyperbaric oxygen, or is laboratory or genetic work. None gives MOTS-c or humanin to participants.

What human studies do show is measurements of the body's own peptides:

  • Exercise. A 2021 review reports that acute high-intensity exercise in humans can raise both humanin and MOTS-c in muscle and plasma. It describes evidence for chronic changes with training as conflicting, and says further work is needed to know whether peptides other than MOTS-c have exercise-like properties (PMID 34520826).
  • Age. Circulating humanin was lower with age in humans and mice (PMID 19623253), and a 2023 review says plasma MOTS-c falls with age (PMID 36761202).
  • Disease. A 2024 meta-analysis (a pooled analysis) of seven studies (602 participants) found blood MOTS-c lower in type 2 diabetes and higher in obesity (PMID 39160573). These are measurements, and they do not show that giving the peptide would change either condition.

A 2022 review describes CB4211 as a MOTS-c analogue and lists its trial (PMID 35499074). The registered trial, NCT03998514 (CohBar, completed April 2021), was a phase 1a/1b (early-stage safety and dose-finding) randomised, placebo-controlled study of subcutaneous single and multiple ascending doses in 88 healthy non-obese people and people with non-alcoholic fatty liver disease. ClinicalTrials.gov, 6 November 2026, shows no posted results, and its dose levels are listed only as "Dose 1" to "Dose 6" and "TBD". PubMed, 6 November 2026, CB4211[tiab]: 0 records. CB4211 is a different compound, so nothing from it can be read as MOTS-c data.

No study has compared MOTS-c and humanin in people. In animals and cells they have been tested side by side without being combined. A 2026 mouse study of atrial fibrillation (an irregular heart rhythm) gave either S14G-humanin (HNG), a humanin analogue, or MOTS-c, and reports that HNG mainly affected cell-adhesion pathways and MOTS-c metabolic processes in an exploratory analysis (PMID 42193373). A 2026 study in cultured human muscle cells found that both HNG and MOTS-c preserved myotube area (the size of the muscle-fibre cells) against dexamethasone, a steroid that causes muscle wasting, but only MOTS-c preserved the fusion index, a measure of how far the cells had fused into muscle fibres (PMID 41732124).

Safety: what is and is not known

No published study gives either peptide to people, so there are no human adverse-event data for either, and the animal studies cannot be used to rank one as safer than the other. The one safety signal found is for humanin in cancer. In a mouse model of triple-negative breast cancer (a breast cancer subtype), systemic humanin reduced the rate of tumour cell death, impaired the effect of chemotherapy, and accelerated tumour growth and the development of spontaneous lung metastases; the authors suggest caution when using exogenous humanin to treat degenerative diseases (PMID 32444831). A 2019 review says the controversy over humanin's role in cancer progression and chemoresistance should be addressed before therapeutic approaches are translated to people (PMID 30582721). The CB4211 registry record lists adverse events as a primary outcome but posts no results.

FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists MOTs-C (MOTS-c) under "Bulk drug substances nominated but withdrawn", which it describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators". Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry for MOTs-C reads: "Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans." Humanin is not named on that page, which is not a finding about its safety.

Combining them

The Epitalon + humanin + MOTS-c longevity stack reviews the theoretical reasoning for combining mitochondrial-derived peptides. The two 2026 studies above, in mice and cultured cells, tested humanin (as the analogue HNG) and MOTS-c in separate groups, and neither abstract describes a group given both.

UK regulatory position

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Verdict — research-question matching

MOTS-c and humanin are both encoded in mitochondrial DNA but have been studied for different things, almost entirely in cells and rodents. No published study has given either to people as a treatment (PubMed, 6 November 2026). In one mouse model of breast cancer, humanin accelerated tumour growth, and a 2019 review describes its role in cancer as controversial. Neither peptide has evidence that it works, or is safe, in people.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

  1. Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-454 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
  2. Hashimoto Y, Niikura T, Tajima H, et al.. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(11) :6336-6341 doi:10.1073/pnas.101133498 · PMID: 11371646
  3. Ying G, Iribarren P, Zhou Y, et al.. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. Journal of Immunology. 2004;172(11) :7078-7085 doi:10.4049/jimmunol.172.11.7078 · PMID: 15153530
  4. Harada M, Habata Y, Hosoya M, et al.. N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochemical and Biophysical Research Communications. 2004;324(1) :255-261 doi:10.1016/j.bbrc.2004.09.046 · PMID: 15465011
  5. Hashimoto Y, Kurita M, Aiso S, Nishimoto I, Matsuoka M. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Molecular Biology of the Cell. 2009;20(12) :2864-2873 doi:10.1091/mbc.e09-02-0168 · PMID: 19386761
  6. Muzumdar RH, Huffman DM, Atzmon G, et al.. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009;4(7) :e6334 doi:10.1371/journal.pone.0006334 · PMID: 19623253
  7. Cobb LJ, Lee C, Xiao J, et al.. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 2016;8(4) :796-809 doi:10.18632/aging.100943 · PMID: 27070352
  8. Zuccato CF, Asad AS, Nicola Candia AJ, et al.. Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases. Expert Opinion on Therapeutic Targets. 2019;23(2) :117-126 doi:10.1080/14728222.2019.1559300 · PMID: 30582721
  9. Moreno Ayala MA, Gottardo MF, Zuccato CF, et al.. Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer. Scientific Reports. 2020;10(1) :8542 doi:10.1038/s41598-020-65381-7 · PMID: 32444831
  10. Woodhead JST, Merry TL. Mitochondrial-derived peptides and exercise. Biochimica et Biophysica Acta. General Subjects. 2021;1865(12) :130011 doi:10.1016/j.bbagen.2021.130011 · PMID: 34520826
  11. Miller B, Kim SJ, Kumagai H, Yen K, Cohen P. Mitochondria-derived peptides in aging and healthspan. Journal of Clinical Investigation. 2022;132(9) doi:10.1172/JCI158449 · PMID: 35499074
  12. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023;14 :1120533 doi:10.3389/fendo.2023.1120533 · PMID: 36761202
  13. Zhou Q, Yin S, Lei X, et al.. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2024;16(1) :200 doi:10.1186/s13098-024-01405-w · PMID: 39160573
  14. Elhusseiny R, Ihsan M, Bellefroid T, et al.. Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells. Physiological Reports. 2026;14(4) :e70791 doi:10.14814/phy2.70791 · PMID: 41732124
  15. Liao Y, Xu J, Jiao Y, et al.. Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines. 2026;14(5) doi:10.3390/biomedicines14051048 · PMID: 42193373
Published: 2026-08-05Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: a mouse study and a review had been presented as human evidence; a claim that exercise raises MOTS-c more than humanin was removed; a mouse cancer finding for humanin and FDA's statement were added; legal statements were replaced.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Continue reading

Stack

Epitalon + Humanin + MOTS-c — Research Evidence Review: What Has Been Studied

Evidence review of Epitalon, Humanin and MOTS-c: lifespan results in mice, small human epitalon reports, no study of the three together, and what is unknown.

Stack

MOTS-c + AOD-9604 — Research Evidence Review: Mitochondrial & Lipolytic Mechanisms

Evidence review of MOTS-c and AOD-9604: what has been studied in animals and in people, what is unknown, and the fact that no study has tested them together.

Stack

SS-31 + Humanin — Research Evidence Review: Mitochondrial Mechanisms

Evidence review of SS-31 (elamipretide, FDA label for Barth syndrome) and Humanin (no human dosing studies): what is known, the trial results and what is unknown.

Peptide

MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Mouse and rat findings, human studies of the body's own MOTS-c, no study giving it to people, and what is unknown.

Peptide

Humanin — Mitochondrial-Derived 24-Amino-Acid Peptide

Humanin is a 24-amino-acid peptide encoded in mitochondrial DNA. Cell and animal findings, a mouse study that found faster tumour growth, and no human dosing study.

Comparison

MOTS-c vs AOD-9604 — Mitochondrial Peptide vs Growth Hormone Fragment

MOTS-c vs AOD-9604: what each has been studied for in animals and in people, the doses published studies used, regulatory and WADA facts, and what no study has compared.

Comparison

SS-31 vs MOTS-c: A Mitochondria-Targeted Drug and an Endogenous Peptide Compared

SS-31 (elamipretide) has an FDA label for Barth syndrome; MOTS-c has no human treatment study. What each evidence base shows, including SS-31 trials that missed their primary endpoints.